Bibliography
- Stewart WF, Liberman JN, Sandler RS, Epidemiology of constipation (EPOC) study in the United States: relation of clinical subtypes to sociodemographic features. Am J Gastroenterol 1994;7:3530-40
- Wald A, Scarpignato C, Kamm MA, The burden of constipation on quality of life: results of a multinational survey. Aliment Pharmacol Ther 2007;26:227-36
- Eutamene E, Bradesi S, Laruche M, Guanylate cyclase C-mediated antinociceptive effects of linaclitide in rodent models of visceral pain. Neurogastroenterol Motil 2010;22:312-e84
- Bharucha AE, Waldman SA. Taking a lesson from microbial diarrheagenesis in the management of chronic constipation. Gastroenterology 2010;138:813-25
- Johanson JF, Morton D, Geenen J, Multicenter, 4 week, double-blind, randomized, placebo-controlled trial of lubiprostone, a locally-acting type-2 chloride channel activator, in patients with chronic constipation. Am J Gastroenterol 2008;103:170-7
- Quigley EM, Vandeplassche L, Kerstens R, Clinical trial: the efficacy, impact of quality of life and safety and tolerability of prucalopride in severe chronic constipation-a 12 week, randomized, double-blind, placebo controlled trial. Aliment Pharmacol Ther 2009;29:315-28
- Goldberg M, Li YP, Mangel AM, Clinical trial: the efficacy and tolerability of velusetrag, a selective 5-HT4 agonist with high intrinsic activity, in chronic idiopathic constipation-a 4 week randomized, double blind, placebo controlled, dose-response study. Aliment Pharm Ther 2010;32:1102-12
- Currie MG, Kurtz CB, Mahajan-Miklos S, Effects of a single dose administration of MD-1100 on safety, tolerability, exposure, and stool consistency in healthy subjects. Am J Gastroenterol 2005;100:S328
- Forte LJ. Uroguanylin and guanylin peptides: pharmacology and experimental therapeutics. Pharmacol Ther 2004;104:137-62
- Hamra FK, Eber SL, Chin DT, Regulation of intestinal uroguanylin/guanylin receptor mediated responses by mucosal acidity. Proc Natl Acad Sci USA 1997;94:2705-10
- Busby RW, Bryant AP, Bartolini WP, Linaclotide, through activation of guanylate cyclase C, acts locally in the gastrointestinal tract to elicit enhanced intestinal secretion and transit. Eur J Pharm 2010;649:328-35
- Lucas KA, Pitari GM, Kazerounian S, Guanylyl cyclases and signaling by cyclic GMP. Pharmacol Rev 2000;52:375-414
- Kurtz CB, Fitch D, Busby RW, Effects of multidose administration of MD-1100 on safety, tolerability, exposure, and pharmcodynamics in healthy subjects. Gastroenterology 2006;130(Suppl 2): A 26
- Andresen V, Camilleri M, Busciglio IA, Effect of 5 days of linaclotide on transit and bowel function in females with constipation-predominant irritable bowel syndrome. Gastroenterology 2007;133:761-8
- Johnston JM, Kurtz CB, Drossman DA, Pilot study on the effects of linaclotide in patients with chronic constipation. Am J Gastroenterol 2009;104:125-32
- Lembo AJ, Johnston JM, MacDougall JE, Efficacy of linaclotide for patients with chronic constipation. Gastroenterology 2010;138:886-95
- Johnston JM, Kurtz CB, MacDougall JE, Linaclotide improves abdominal pain and bowel habits in a phase IIb study of patients with irritable bowel syndrome. Gastroenterology 2010;139(6):1877-86
- Lembo A, Schneier H, Lavins BJ, Efficacy and safety of once daily linaclotide administered orally for 12-weeks in patients with chronic constipation: results from 2 randomized, double-blind, placebo-controlled phase 3 trials (abstract 286). Presented at Digestive Disease Week (DDW) 2010 in New Orleans, LA
- Bharucha AE, Linden DR. Linaclotide-a secretagogue and antihyperalgesic agent-what next? Neurogastro Motil 2010;22:227-31